journal article·2025-06Open access

Sorafenib-loaded metal-organic framework nanoparticles for anti-hepatocellular carcinoma effects through synergistically potentiating ferroptosis and remodeling tumor immune microenvironment

Yuanliang Yan, Jun Hu, Ning Han, Hai-Tao Li, Xiaoxin Yang, Liu-Gen Li, Zhijie Xu, Fada Xia, Jie Li, Tong-fei Li, Ruochan Chen

Abstract

Sorafenib (Sor), a multi-kinase inhibitor, serves as the first-line systemic therapeutic drug for advanced hepatocellular carcinoma (HCC). Unfortunately, clinical benefit was confirmed in only a minority of patients, limiting clinical application of Sor. Using nanotechnology to enhance the therapeutic effect of anti-cancer drugs has become a major trend. Accordingly, a Fe(III)-based metal-organic framework (MOF) nanocarrier encapsulating Sor (Sor@Fe-MOF) with ferroptosis/immune activation functions was constructed for HCC therapy. In vivo and in vitro assays demonstrated that these prepared Sor@Fe-MOF nanoparticles (NPs) exhibited favorable therapeutic activities against HCC, characterized by increasing ferroptosis and remodeling tumor immune microenvironment. Compared with free Sor, Sor@Fe-MOF produced the additive effects that induce ferroptotic cell death in HCC cells through downregulating GPX4 and SLC7A11 and upregulating ACSL4. Using orthotopic tumor mouse model and humanized PBMC mouse model, we also found that Sor@Fe-MOF obviously activated the anti-HCC immunity via increasing tumor infiltration of CD8 + T cells. Upon internalization by CD8 + T lymphocytes, Sor@Fe-MOF effectively facilitated the activation and tumor penetration of these immune cells. No obvious morphological changes of mice organs implied the distinctive biological security during Sor@Fe-MOF treatment. Taken together, our findings highlighted the excellent capacity of Sor@Fe-MOF to facilitate ferroptosis and remodel immune microenvironment, consequentially improving therapeutic response of Sor. These prepared Sor@Fe-MOF NPs could be function as a promising alternative strategy for HCC treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · MicroRNA in disease regulation · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (47)

Show source-provided references
1. Precision models in hepatocellular carcinoma10.1038/s41575-024-01024-w ↗
2. Diagnostic and prognostic value of protein post-translational modifications in hepatocellular carcinoma
3. FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma10.1186/s40001-023-01411-0 ↗
4. Recent advances in systemic therapy for hepatocellular carcinoma10.1186/s40364-021-00350-4 ↗
5. Survival trends in sorafenib for advanced hepatocellular carcinoma: a reconstructed individual patient data meta-analysis of randomized trials10.1159/000529824 ↗
6. Trends of clinical outcomes of patients with advanced hepatocellular carcinoma treated with first-line sorafenib in randomized controlled trials10.1159/000521625 ↗
7. Real-world evidence of sorafenib for the treatment of hepatocellular carcinoma: a single-center study10.4103/jcrt.jcrt_308_21 ↗
8. RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α–XBP1s pathway10.1038/s41420-021-00696-6 ↗
9. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress10.1016/j.drup.2023.101015 ↗
10. Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma
11. Co-delivery of doxorubicin/sorafenib by DNA-decorated green ZIF-67-based nanocarriers for chemotherapy and hepatocellular carcinoma treatment10.1016/j.envres.2023.115589 ↗
12. Dual-drug controllable co-assembly nanosystem for targeted and synergistic treatment of hepatocellular carcinoma10.1016/j.jcis.2023.11.109 ↗
13. Establishment of an ovarian cancer exhausted CD8+T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq10.1186/s40001-024-01948-8 ↗
14. A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade
15. Photothermal and host immune activated therapy of cutaneous tuberculosis using macrophage targeted mesoporous polydopamine nanoparticles
16. A review on PCR and POC-PCR - a boon in the diagnosis of COVID-1910.2174/1573412918666220509032754 ↗
17. Recent development of pH‐responsive theranostic nanoplatforms for magnetic resonance imaging‐guided cancer therapy10.1002/EXP.20220002 ↗
18. Mechanism of hard-nanomaterial clearance by the liver10.1038/nmat4718 ↗
19. TCEB2/HIF1A signaling axis promotes chemoresistance in ovarian cancer cells by enhancing glycolysis and angiogenesis10.1186/s40001-024-02050-9 ↗
20. Bifunctional cascading nanozymes based on carbon dots promotes photodynamic therapy by regulating hypoxia and glycolysis10.1021/acsnano.3c03169 ↗
21. Ferroptosis in regulating treatment tolerance of digestive system tumors10.14218/CSP.2024.00018 ↗
22. Ferroptosis: from basic research to clinical therapeutics in hepatocellular carcinoma
23. Ropivacaine prompts ferroptosis to enhance the cisplatin-sensitivity of human colorectal cancer through SIRT1/Nrf2 signaling pathway10.1016/j.cbi.2024.111163 ↗
24. Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope10.1186/s12943-024-02130-8 ↗
25. Ultrasound-enhanced dual-responsive bismuth nanocatalysts for alleviating tumor hypoxia and promoting breast cancer sonodynamic-immunotherapy10.1016/j.cej.2025.160292 ↗
26. Interpretation of T cell states from single-cell transcriptomics data using reference atlases10.1038/s41467-021-23324-4 ↗
27. Cd8 enhancer E8I and Runx factors regulate CD8α expression in activated CD8+ T cells10.1073/pnas.1105835108 ↗
28. Temporal and spatial topography of cell proliferation in cancer10.1038/s41556-022-00860-9 ↗
29. Prognostic relevance of cell proliferation in head and neck tumors10.1093/annonc/mdh299 ↗
30. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma10.1001/jamaoncol.2023.2677 ↗
31. N6-methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression10.1158/0008-5472.CAN-23-1916 ↗
32. KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma10.1186/s40364-022-00361-9 ↗
33. Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer10.1038/s41419-024-06493-0 ↗
34. Mechanisms of drug resistance in HCC10.1097/HEP.0000000000000237 ↗
35. Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials10.1186/s40001-023-01539-z ↗
36. Progress in application of nanotechnology in sorafenib10.1166/jbn.2021.3061 ↗
37. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma10.1039/D0BM00295J ↗
38. Reducing postoperative recurrence of early‐stage hepatocellular carcinoma by a wound‐targeted nanodrug10.1002/advs.202200477 ↗
39. Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma10.1186/s12951-021-01095-w ↗
40. Pore structure compartmentalization for advanced characterization of metal–organic framework materials10.1021/acs.jcim.3c01872 ↗
41. Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of Melanoma10.1186/s12951-023-02146-0 ↗
42. Dual-stimuli responsive smart nanoprobe for precise diagnosis and synergistic multi-modalities therapy of superficial squamous cell carcinoma10.1186/s12951-022-01759-1 ↗
43. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B10.1016/j.jhep.2021.08.029 ↗
44. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL‐12 in vivo10.1111/liv.12284 ↗
45. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity10.1016/j.canlet.2022.215880 ↗
46. Overcoming tumor hypoxic bismuth-based ternary heterojunctions enable defect modulation-augmented tumor sonocatalytic immunotherapy10.1016/j.biomaterials.2024.122962 ↗
47. Nanoagonist‐mediated GSDME‐dependent pyroptosis remodels the inflammatory microenvironment for tumor photoimmunotherapy10.1002/adfm.202200811 ↗